Clinical trial NCT05439460
Conditions: Pulmonary Arterial Hypertension
Sponsor: Stanford University
Start date: 2012-01-01; Completion date: 2014-06-01
Enrollment: 15 participants; Allocation: NON_RANDOMIZED; Intervention model: SEQUENTIAL

Brief summary:
Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures. The severity of baseline PAH correlates with the incidence of major complications, such that those with PAP higher than their systemic blood pressure (SBP) had a 8 fold increased risk of complications. These children present for procedures where an acute exacerbation of their chronic illness-termed Pulmonary Hypertensive (PH)crisis, can occur, often resulting in death if not detected and managed expeditiously. Unfortunately there is little data and no consensus in the pediatric literature on how PH crisis should be managed.

\--------------------------------------------------------------------------------

Detailed description:
Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures. The severity of baseline PAH correlates with the incidence of major complications, such that those with PAP higher than their systemic blood pressure (SBP) had a 8 fold increased risk of complications. These children present for procedures where an acute exacerbation of their chronic illness-termed PH crisis, can occur, often resulting in death if not detected and managed expeditiously. Unfortunately there is little data and no consensus in the pediatric literature on how PH crisis should be managed. Over the last 10 years we have developed considerable expertise in managing children with PAH and preventing and treating their acute crisis, using a medication called phenylephrine. This medication is routinely used to increase the blood pressure in patients (adults and children) to treat hypotension. Our theory has been that by increasing SBP, we can increase the blood flow to the coronary arteries and prevent the right ventricle from failing acutely. The latter results in catastrophic hypotension, heart arrythmias and death. There is no consensus or protocol guiding the management of the acute crisis. This purpose of this study is to close that gap.

Arms: arm 1: Phenylephrine will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery. arm 2: Epinephrine will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery. arm 3: Arginine Vasopressin will be administered once the child is under anesthesia and the interventional cardiologist has measured the pressures in the pulmonary artery.
Interventions: intervention 1: Phenylephrine intervention 2: Epinephrine intervention 3: Arginine Vasopressin
Intervention descriptions: intervention 1: 5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration. intervention 2: 5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration. intervention 3: 5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.

Protocol documents:
Prot_000.pdf: 
 
 
 
 
 
 
 
Management of Acute Pulmonary Hypertensive Crisis in Children with 
Known Pulmonary Arterial Hypertension 
Study Protocol 
NCT05439460 
November 8, 2011 
 
 


Scientific protocol 
 
1) 
Name of study: Management of acute pulmonary hypertensive crisis in children with    
         pulmonary arterial hypertension (PAH) 
 
 
2)     PI and other key investigators or key study personnel: 
          Chandra Ramamoorthy, MD 
          Glyn David Williams, MD 
          Jeffrey Feinstein, MD 
          Danton Samuel Char, MD 
          Claudia Benkwitz, MD 
          
, CRC                 
    
3)      Specific source of institutional funding:  
          Internal or Departmental funding  
 
4)      List of sources from which you are seeking funds (or have sought funding) for this  
          project: 
         Once we have pilot data we will apply for external funding. 
 
5)      Specific Aims and basic hypothesis including an explicit primary hypothesis or goal 
          From this prospective study we will demonstrate that 
          1) Phenylephrine can be safely used to treat PH crisis     
          2) Arginine vasopressin may be better since it   decreases pulmonary artery pressure   
              while increasing systemic blood pressure  
          3) Epinephrine, the drug most commonly used for resuscitation, will be the least effective   
              in managing PH crisis. 
 
6)      General background (2 page maximum including published preclinical and animal data  
          supporting basic hypothesis, if relevant). 
 
           PAH increases perioperative morbidity and mortality in children (1-4).  Acute exacerbations    
           of PAH, commonly referred to as PH crisis, must be recognized early and managed  
           expeditiously to avoid cardiac arrest and death.  Results of resuscitation following arrest  
           are poor in this population therefore rapid recognition and management are essential.  
           PAH crisis may present as systemic hypotension with or without EKG changes of ischemia  
          and associated increase in mean PA pressure.  The goal of resuscitation in this situation  
          must be to increase aortic pressure and cardiac-output so right heart coronary filling and  
          output are maintained.  However there is no consensus on what is the optimal therapy to  
          achieve this.  While administration of pulmonary vasodilators, systemic or inhaled, may  
           be effective and the patient may already be on such therapy, these agents may not  
          provide rapid additional decreases in pulmonary vasculature required to support the 
          failing right ventricle.  
           
           Although vasopressors have been widely used to resuscitate the right ventricle, this  


Scientific protocol 
 
practice is controversial.  Vasopressors such as nor-epinephrine, phenylephrine, isuprel and 
dobutamine have been advocated in managing PH patients in the intensive care units.   
However, there is no consensus on the optimal agent or dosing regimens. 
 
Epinephrine, the vasopressor a part of most ACLS protocols, has instant appeal for reasons of 
cost and ease of availability.  The theoretical reasons to avoid catecholamines such as 
epinephrine or nor epinephrine, would be the increase in heart rate (Beta agonist effect), which 
would further reduce coronary filling and worsen myocardial ischemia, despite the increase in 
SVR caused by systemic vasoconstriction (alpha receptor mediated effect).  In patients with 
PAH, depending on its severity, coronary artery filling of both ventricles occurs mostly during 
diastole and increases in HR could reduce the coronary flow.  There are no trials of epinephrine 
in acute PH crisis.  However norepinephrine has been used successfully in an observational 
study of newborns with PPHN (Persistent Pulmonary Hypertension of Newborn), with 
improvements in echo derived measures of LV output, LV pressure, and a decrease in 
pulmonary/systemic pressure ratio. Additional neonatal animal data and data in adult humans 
also support the use of norepinephrine in PPHN and PHN respectively.  There are no systematic 
trials in pediatric patients with chronic PHN, with acute exacerbations.  Phenylephrine is a pure 
alpha agonist and increases the both SVR and PVR without increases in HR.  However the 
increase in SVR with resultant improved coronary perfusion and despite the increase in PVR, 
the ratio of SVR/PVR favors improved interventricular interaction.  Studies of phenylephrine 
showing benefits or not are in adults with PHN10, 11. 
 
Arginine vasopressin is a systemic vasopressor used in vasodilatory shock and cardiopulmonary 
resuscitation in both adults and children. It has been used widely for managing acute 
gastrointestinal bleeds in both adults and children (6,9). This would appear to be an ideal agent 
as it is not a catecholamine hence has no stimulating effects on heart and produces systemic 
vasoconstriction. In addition, it has pulmonary vasodilatory effects (6). AVP causes endothelial 
dependent vasodilatation by binding to endothelial V1 receptor.   Recent case reports discuss 
the use of AVP or a synthetic analogue in children with PAH in the perioperative setting and in 
septic shock (9-review ). 
 
Traditionally at LPCH, we have used phenylephrine for hypotension and management of PAH 
crisis. Annually about 40 children undergo cardiac catheterization for diagnosis or follow up of 
PAH.  From a 12 month review of anesthesia data, we noted a 1% use of phenylephrine (0.5-1 
µg/kg bolus administered one or more times) to manage systemic hypotension and or PAH 
during the procedure. In 4 patients with PAH undergoing cardiac catheterization, detail records 
were available to assess hemodynamic information.  Of the 3, there was no change in PVR/SVR 
in one 1 (equivocal), in another the ratio increased (not a benefit) and in the other 2 the ratio 
decreased (benefit).  In all 4, cardiac indexes were maintained after phenylephrine.  We also 
noted from this data that the effects of phenylephrine were not detectable beyond 5 minutes 
and pressures returned to baseline. In addition anecdotal evidence from our institution on the 
use of phenylephrine in the operating room in children with PAH undergoing non-cardiac 
procedures to treat acute PH crisis exists. 
 


Scientific protocol 
 
 
7)      Preliminary unpublished data (1 page maximum) 
          In 4 patients with PAH we had complete hemodynamic data when phenylephrine was 
          required. In 2 of the 4 the PVR/SVR change was beneficial; with no change in 1 and in  
          another a small increase in PVR/SVR.  We have no experience with AVP in this population  
          in the cath lab. Epinephrine has never been our drug of choice, although an anecdotal  
          report of significant tachycardia with a 5µg/kg dose was recorded. 
 
 
8)      Experimental design and data analysis, including inclusion and exclusion criteria, statistical  
         basis for the number of subjects to be enrolled, the statistical plan for analyzing at least 
         the primary hypothesis, matrix showing procedure plan for each study visit, data safety  
         monitoring plan (4 pages maximum) 
          
Study protocol:  This is an open label study which will be done in 3 phases, allowing us to assess 
safety and efficacy of treatment as the study progresses.  
Phase 1: Following baseline hemodynamic catheter measurements, baseline transthoracic echo 
will be obtained to assess the position of interventricular septum.  Following these 
measurements a 1 µg/kg bolus of phenylephrine will be given and hemodynamic data 
continuously recorded for up to 5 minutes after the bolus.  We expect that phenylephrine will 
increase both mean pulmonary (MPAP) and systemic arterial pressure (MSAP) but the MSAP 
increase will exceed MPAP increase, favoring coronary arterial blood flow to the right ventricle.  
Further if cardiac index is unchanged then the increase in SVR will be greater than increase in 
PVR such that the ventricular septal shift toward the right will favor improved LV output.  In 
addition to making hemodynamic catheter measurements, transthoracic echocardiography will 
be repeated 2 minutes following bolus.   
End Points of the study:  Table 2 outlines the hemodynamic measurements that will be made at 
baseline and at 2 minutes after end of bolus.  Adverse events will be described as a 20% 
increase in mean PAP or a 20% increase in PVRI, or a 20% decrease in CI or MVO2.  After 
studying 10 consequential patients with phenylephrine we will then start the next phase of the 
study.  
Phase 2: epinephrine bolus as 1µ/kg will be administered and measurements repeated. There 
will be 10 patients in this category. The dose chosen is based on the current “dwindle” dose 
used in the ICU’s to treat sudden hypotension.  The full code dose of 10µg/kg will be excessive 
in this population. As we have anecdotal report of tachycardia even with 5µg/kg IV in this 
population.  
Phase 3:  These will be patients with a known diagnosis of PAH undergoing cardiac 
catheterization. This is a dose escalation study of arginine vasopressin as a treatment to alter 
the SVRI/ PVRI ratio in patients with PAH.  Baseline data will be collected as in phase 1.  
Following baseline data collection, a single dose of AVP will be administered.  Dose of AVP used 
in children with septic shock is 0.01-0.03 units/kg and the duration of effect is 30 minutes.   For 
the purposes of this study we will use of 0.01 units/kg as the dose.  This dose might have no 
significant effect on any of the measured hemodynamics.  If this pattern is consistent in 5 
patients then we will increase the dose to 0.02units/kg and reassess the hemodynamics in an 


Scientific protocol 
 
additional 5 patients.  If this dose also does not alter hemodynamics and there are adverse 
events then we will increase the dose to 0.03 units/kg in additional 5 patients No further dose 
escalation is planned.  Dr Pearl, chairman of Anesthesia has anecdotal reports administering 1 
unit of AVP to adults in PAH crisis with significant improvement.  Our initial dose of 0.01 u/kg 
may be insufficient as children have a larger volume of distribution. However we have never 
systematically studied this medication in this group and are conservative. 
 
Inclusion criteria: Patients 1-18 years of age with diagnosis of PAH either by previous cardiac 
catheterization or by echocardiography. 
 
Exclusion criteria: PAH patients with intracardiac shunts; failure to obtain consent; emergency cases 
done at night or weekends where staff may not be available for following the protocol 
 
For the current study a power analysis was not performed. Annually about 50 cardiac catheterization are 
performed in children with PH. About 20% have intra-cardiac shunts and we expect 10% refusal rate for 
consent.  We expect to draw from the remaining 70% to get pilot data.   With this preliminary data we 
plan to compute the statistical power.  This question has not been studied systematically in children and 
we are confident that preliminary results will be valuable for planning future studies and funding.  
 
Table 1: Demographic data:  
Name 
Age 
Gender 
Height 
Weight 
BSA 
Diagnosis 
Current Medications 
Date of Procedure 
 
 
Table 2: Data Collection during the study 
Drug Name and Dose: 
Parameter 
Baseline  
Post treatment 
HR (beats/min) 
 
 
ECG 
 
 
Systemic Systolic pressure (SSAP) 
 
 
Diastolic (SDBP) 
 
 
Mean (SMAP) 
 
 
Pulmonary Systolic  
 
 
Pulmonary Diastolic 
 
 
Pulmonary Mean (MPAP) 
 
 
RVEDP 
 
 
RAP 
 
 
PCWP 
 
 
CI 
 
 
MVO2 
 
 
SaO2 
 
 


Scientific protocol 
 
Calculated PVRI/SVRI  
 
 
Transthoracic Echo (septal 
position) 
 
 
 
   
Data Safety Monitoring Plan:  
Protocol Director will be the monitoring entity. In addition to height, weight, age and gender the 
following will be collected: Heart rate, blood pressure: systolic, diastolic, mean; ECG, mixed venous 
oxygen saturation, arterial blood gas, pulmonary artery pressure: systolic, diastolic and mean, 
pulmonary capillary wedge pressure. If there are allergic reactions to any of the medications that will be 
noted under adverse events and the events reviewed carefully. This will help us determine if any 
changes need to be made to the protocol. 
    
Unanticipated events will be reported within 10 days to the IRB. 
  
Study data will be assessed at the end of each phase. If any of the medications result in 
hemodynamic responses that are unfavorable to the patient, such as decrease in systemic blood 
pressure but increased pulmonary artery pressure we will stop to review data and decide whether we 
need to change what we are doing.  
 
9)     Significance (1 paragraph or less) 
        Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the  
        pulmonary arteries (PAP) are high4. PAH increases the risk of adverse events, including  
        risk of death, during and or after procedure. The severity of baseline PAH correlates with 
        the incidence of major complications, such that those with PAP higher than their systemic  
        blood pressure (SBP) had a 8 fold increased risk of complications. These children present  
         for procedures where an acute exacerbation of their chronic illness-termed PH crisis, can  
         occur, often resulting in death if not detected and managed expeditiously. Unfortunately  
        there is little data and no consensus in the pediatric literature on how PH crisis should be  
        managed. Over the last 10 years we have developed    considerable expertise in managing  
        children with PAH and preventing and treating their    acute crisis, using a medication called  
        phenylephrine. This medication is routinely used to increase the blood pressure in patients  
        (adults and children) with hypotension. Our theory has been that by increasing SBP, we 
        can increase the blood flow to the coronary    arteries and prevent the right ventricle from  
        failing acutely. The latter can result in catastrophic hypotension, heart arrhythmias and  
        death. There is no consensus or protocol guiding the management of the acute crisis. This     
        purpose of this study is to close that gap.  
 
10)   Key references: 
 
1. Williams GD, Maan H, Ramamoorthy C, Kamra K, Bratton SL, Bair E, Kuan CC, Hammer GB, 
Feinstein JA: Perioperative complications in children with pulmonary hypertension undergoing 
general anesthesia with ketamine. Paediatric anaesthesia 2010; 20: 28-37 


Scientific protocol 
 
2. 
Carmosino MJ, Friesen RH, Doran A, Ivy DD: Perioperative complications in children with 
pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesthesia 
and analgesia 2007; 104: 521-7 
3. 
Ramamoorthy C, Haberkern CM, Bhananker SM, Domino KB, Posner KL, Campos JS, 
Morray JP: Anesthesia-related cardiac arrest in children with heart disease: data from the 
Pediatric Perioperative Cardiac Arrest (POCA) registry. Anesthesia and analgesia 2010; 110: 
1376-82 
4. Friesen RH, Williams GD: Anesthetic management of children with pulmonary arterial 
hypertension. Paediatric anaesthesia 2008; 18: 208-16 
 
5. Abman SH: Pulmonary hypertension in children: a historical overview. Pediatric critical care 
medicine : a journal of the Society of Critical Care Medicine and the World Federation of 
Pediatric Intensive and Critical Care Societies 2010; 11: S4-9 
6 
Evora P, Pearson P, Schaff H: Arginine vasopressin induces endothelium-dependent 
vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 
1993; 103: 1241-1245 
7 
 
Price LC, Wort SJ, Finney SJ, Marino PS, Brett SJ: Pulmonary vascular and right 
ventricular dysfunction in adult critical care: current and emerging options for management: a 
systematic literature review. Critical care 2010; 14: R169 
8 
Taylor MB, Laussen PC: Fundamentals of management of acute postoperative 
pulmonary hypertension. Pediatric critical care medicine : a journal of the Society of Critical 
Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2010; 
11: S27-9 
9 
Wolf A: Vasopressin in paediatric practice. Paediatric anaesthesia 2008; 18: 579-81 
10 
Zamanian RT, Haddad F, Doyle RL, Weinacker AB: Management strategies for patients 
with pulmonary hypertension in the intensive care unit*. Critical care medicine 2007; 35: 2037-
2050 
11 
Kleinman ME, de Caen AR, Chameides L, Atkins DL, Berg RA, Berg MD, Bhanji F, Biarent 
D, Bingham R, Coovadia AH, Hazinski MF, Hickey RW, Nadkarni VM, Reis AG, Rodriguez-Nunez 
A, Tibballs J, Zaritsky AL, Zideman D: Part 10: Pediatric basic and advanced life support: 2010 
International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care 
Science With Treatment Recommendations. Circulation 2010; 122: S466-515 
 
 

SAP_001.pdf: 
 
 
 
Management of Acute Pulmonary Hypertensive Crisis in Children With 
Known Pulmonary Arterial Hypertension 
Statistical Analysis Plan 
NCT05439460 
May 1, 2016 
 
For analysis, baseline systolic, diastolic, and mean aortic and pulmonary artery pressures were 
determined by averaging the data for the 30 seconds immediately prior to the administration of study 
drug. The peak drug effect was defined as the highest systemic blood pressure and the simultaneous 
pulmonary artery pressure after administration of study drug. The ratio of systolic pulmonary artery 
pressure-to-systolic systemic blood pressure was calculated at baseline and peak drug effect. 
The primary outcome variable was a change in Rp:Rs after drug administration. Secondary outcomes 
were the changes in systemic and pulmonary artery pressure, pulmonary artery occlusion pressure, PVR, 
SVR, and cardiac index after study drug administration. 
Statistical comparisons of continuous variables within groups before and after drug administration were 
made using a paired t test (IBM SPSS Statistics, Armonk, NY); statistical significance was set at a p value 
of less than 0.05.